CNS Anticancer Drug Discovery and Development Conference White Paper

Victor A Levin; Peter J Tonge; James M Gallo; Marc R Birtwistle; Arvin C Dar; Antonio Iavarone; Patrick J Paddison; Timothy P Heffron; William F Elmquist; Jean E Lachowicz; Ted W Johnson; Forest M White; Joohee Sul; Quentin R Smith; Wang Shen; Jann N Sarkaria; Ramakrishna Samala; Patrick Y Wen; Donald A Berry; Russell C Petter

doi:10.1093/neuonc/nov169

CNS Anticancer Drug Discovery and Development Conference White Paper

Neuro Oncol. 2015 Nov;17 Suppl 6(Suppl 6):vi1-26. doi: 10.1093/neuonc/nov169.

Authors

Victor A Levin¹, Peter J Tonge¹, James M Gallo¹, Marc R Birtwistle¹, Arvin C Dar¹, Antonio Iavarone¹, Patrick J Paddison¹, Timothy P Heffron¹, William F Elmquist¹, Jean E Lachowicz¹, Ted W Johnson¹, Forest M White¹, Joohee Sul¹, Quentin R Smith¹, Wang Shen¹, Jann N Sarkaria¹, Ramakrishna Samala¹, Patrick Y Wen¹, Donald A Berry¹, Russell C Petter¹

Affiliation

¹ Kaiser Permanente, Redwood City, California, USA (V.A.L.); University of Texas MD Anderson Cancer Center, Houston, TX, USA (V.A.L.); University of California, San Francisco, CA, USA (V.A.L.); SUNY Stony Brook University, Stony Brook, NY, USA (P.J.T.); Icahn School of Medicine at Mount Sinai, New York, NY, USA (J.M.G., M.R.B., A.C.D.); Columbia University Institute for Cancer Genetics, New York, NY, USA (A.I.); Fred Hutchinson Cancer Research Center, Seattle, WA, USA (P.J.P.); Genentech, Inc., South San Francisco, CA, USA (T.P.H.); University of Minnesota School of Pharmacy, Minneapolis, MN, USA (W.F.E.); Angiochem, Inc., Montreal, Quebec, Canada (J.E.L.); Pfizer Oncology, San Diego, CA, USA (T.W.J.); Massachusetts Institute of Technology, Cambridge, MA, USA (F.M.W.); US Food and Drug Administration, Silver Spring, MD, USA (J.S.); Texas Tech University School of Pharmacy, Amarillo, TX, USA (Q.R.S., R.S.); NewGen Therapeutics, Inc., Menlo Park, CA, USA (W.S.); Mayo Clinic, Rochester, MN, USA (J.N.S.); Dana-Farber Cancer Institute, Boston, MA, USA (P.Y.W.); University of Texas MD Anderson Cancer Center, Houston, TX, USA (D.A.B.); Celgene Avilomics Research, Bedford, MA, USA (R.C.P.).

Abstract

Following the first CNS Anticancer Drug Discovery and Development Conference, the speakers from the first 4 sessions and organizers of the conference created this White Paper hoping to stimulate more and better CNS anticancer drug discovery and development. The first part of the White Paper reviews, comments, and, in some cases, expands on the 4 session areas critical to new drug development: pharmacological challenges, recent drug approaches, drug targets and discovery, and clinical paths. Following this concise review of the science and clinical aspects of new CNS anticancer drug discovery and development, we discuss, under the rubric "Accelerating Drug Discovery and Development for Brain Tumors," further reasons why the pharmaceutical industry and academia have failed to develop new anticancer drugs for CNS malignancies and what it will take to change the current status quo and develop the drugs so desperately needed by our patients with malignant CNS tumors. While this White Paper is not a formal roadmap to that end, it should be an educational guide to clinicians and scientists to help move a stagnant field forward.

Keywords: brain metastasis; chemotherapy; glioma; medulloblastoma; pharmacokinetics; pharmacology.

Publication types

Congress
Research Support, Non-U.S. Gov't

MeSH terms

Animals
Antineoplastic Agents / therapeutic use*
Central Nervous System Neoplasms / drug therapy*
Clinical Trials as Topic
Disease Models, Animal
Disease-Free Survival
Drug Discovery*
Endpoint Determination
Glioma / drug therapy*
Humans
Medulloblastoma / drug therapy*
Treatment Outcome

Substances

Antineoplastic Agents

Abstract

Publication types

MeSH terms

Substances

Grants and funding